WINDSOR, ON / ACCESSWIRE / June 25, 2015 / The Wealthy Biotech Trader (or “WBT”), an Investment Newsletter focused on showing everyday Investors new opportunities in rapidly growing, little-known, Biotech stocks making news and subsequent market moves, would like to report on the recent move PositiveID (PSID) has made in the market. WBT reiterates PositiveID (PSID) as their pick for the summer and into the fall.
After our initial profile over 6 weeks ago on May 17th, a significant run-up in share price, and a few copycat articles trying to claim our success, our readers are banking some serious gains on PSID. Traders were told to watch for developments on PSID’s lead product the Firefly Dx to act as a potential catalyst for the stock, the company did just that-click this link for the news:PositiveID Successfully Tests 12 Different Assays on Its Firefly Dx Prototype System.
Things at PSID seem to be progressing as planned and the market has rewarded management for that. WBT feels the most crucial market catalyst for the Company could be just around the corner as the company looks to shrink the prototype of the Firefly DX unit they’ve been working on into a unit that is handheld, moving them towards the doorstep of commercialization. The huge market potential (for the Firefly as well as the stock) is outlined in WBT’s initial report which can be read by clicking here: The $27 Billion Market Most Investors Never Heard Of– And The Hottest Stocks In The Space.
Other Biotech stocks recently profiled include Advaxis (ADXS) which has since undergone a 20% correction amidst the moderately positive news of the Company being added to both the Russell 3000 as well as Global Index. Sometimes being added to indexes can increase trading in a company’s stock as it may be required to be purchased by Managers of certain index funds. This news may have been over shadowed by the release of the Company’s financials ending April 30th, 2015 showing that the Company burned through almost $10 Million in only 6 months.
On WBT’s last publication Propanc Health Group (PPCH) was another Company of mention, and since then has released three positive press releases to a muted reaction which may be due to doldrums of summer trading or the technical traders of the stock letting the chart rest temporarily. One thing is for certain– See ThruEquity, a stock research firm, seems to think the stock is fairly valued at $1.52 which is wildly higher than its current price.
The fourth Company mentioned in last week’s installment was TapImmune (TPIV), TPIV has absolutely gone parabolic. One may opt to use the term vertical instead… Nevertheless, traders who bought this stock after we mentioned it have basically doubled their money as the Company recently released news of positive phase I results of their breast cancer drug candidate multi-peptide HER2/neu vaccine. However, charts like TPIV’s, charts that are severely overbought, can be dangerous, so smart investors may choose to lock in gains and wait for a pull-back to re-enter.
The Wealthy Biotech Trader is always researching new trade ideas which have the makings for large market moves. Traders are urged to follow our parent outlet, The Wealthy Venture Capitalist on social media (see below) to stay apprised. We are an anti-email media outlet, and as such will only be releasing our reports/ updates/ news through Twitter and Facebook as well as newswire.
GET BREAKING NEWS FROM US:
This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. The Wealthy Biotech Trader and its employees are not a Registered Investment Advisors, Broker Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The Wealthy Biotech Trader encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and The Wealthy Biotech Trader makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day closing price and the high of day price during our promotional coverage.
The Wealthy Biotech Trader’s parent company has been and will continue to be compensated $25,000 per month by PositiveID. The Wealthy Biotech Trader’s controlling parent company has also been compensated $62,500 by PositiveID in the form of a convertible note and readers should understand that they will convert this note into common shares and sell them into the market as soon as the statutory 144 hold period has lapsed. The Wealthy Biotech Trader’s parent company has been and will be compensated roughly $5,000 per month by Propanc Heath Group. The Wealthy Biotech Trader’s controlling parent company has also been compensated $60,000 by Propanc Heath Group in the form of a convertible note and readers should understand that they will convert this note into common shares sell them into the market as soon as the statutory 144 hold period has lapsed.
Readers must visit our website at www.wealthyventurecapitalist.com in order to view our entire disclaimer which covers most of the risks, biases and liability releases to have a full understanding after reading this article.
SOURCE: The Wealthy Biotech Trader